Imexpharm Management

Management Kriterienprüfungen 3/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Dao Tran

Geschäftsführender

₫5.0b

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	11.5yrs
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	5.1yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	3yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Dao Tran (72 yo)

11.5yrs

Amtszeit

₫5,032,239,598

Vergütung

Ms. Dao Thi Tran has been General Director at Imexpharm Corporation since May 2013 and serves as its Member of Executive Board. Ms. Tran had been Vice Chairwoman of the Board of Directors at Imexpharm Phar...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Dao Tran	General Director	11.5yrs	₫5.03b	keine Daten
Tuan Ngo	Deputy General Director & Member of Executive Board	9.7yrs	₫2.43b	keine Daten
Nhung Huynh	Deputy General Director & Member of Executive Board	no data	₫2.03b	keine Daten
Phuong Van Le	Deputy General Director & Member of Executive Board	no data	₫2.99b	keine Daten
Le Kim Nguyen	Secretary of the Board of Directors	9.3yrs	₫442.47m	keine Daten
Duy Nguyen	Deputy General Director	less than a year	keine Daten	keine Daten
Thanh Nguyen	Deputy General Director & Member of Executive Board	less than a year	keine Daten	keine Daten
Hung Hoang	Chief Accountant & Director	less than a year	keine Daten	keine Daten

5.1yrs

Durchschnittliche Betriebszugehörigkeit

48yo

Durchschnittliches Alter

Erfahrenes Management: IMPDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (5.1 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Dao Tran	General Director	no data	₫5.03b	keine Daten
Hung Hoang	Chief Accountant & Director	less than a year	keine Daten	keine Daten
Vinh Thi Han	Non-Executive Director	6.6yrs	₫644.00m	keine Daten
Hung Truong	Non-Executive Director	4.5yrs	₫644.00m	keine Daten
Suyong Chung	Director	1.6yrs	₫284.31m	keine Daten

3.0yrs

Durchschnittliche Betriebszugehörigkeit

50yo

Durchschnittliches Alter

Erfahrener Vorstand: IMPDie Vorstandsmitglieder gelten als erfahren (3 Jahre durchschnittliche Amtszeit).

Imexpharm Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Imexpharm Corporation, Annual General Meeting, Apr 26, 2024

Imexpharm Corporation Approves Election of Hoang Duc Hung as an Independent Member of the Board of Directors

Imexpharm Corporation Appoints Chun Chaerhan as Chairperson of the Board of Directors

No independent directors

Imexpharm Corporation Announces Personnel Change

No independent directors

Recent updates

Third quarter 2024 earnings released: EPS: ₫436 (vs ₫404 in 3Q 2023)

New minor risk - Share price stability

Price target increased by 9.2% to ₫78,485

Second quarter 2024 earnings released: EPS: ₫794 (vs ₫851 in 2Q 2023)

Investor sentiment improves as stock rises 20%

Upcoming dividend of ₫1,000 per share

Imexpharm Corporation Announces Dividend for the Year 2023, Payable on July 23, 2024

First quarter 2024 earnings released

Imexpharm Corporation, Annual General Meeting, Apr 26, 2024

Full year 2023 earnings released: EPS: ₫3,637 (vs ₫2,810 in FY 2022)

Imexpharm Corporation Approves Election of Hoang Duc Hung as an Independent Member of the Board of Directors

Third quarter 2023 earnings released: EPS: ₫889 (vs ₫817 in 3Q 2022)

Upcoming dividend of ₫1,000 per share at 1.5% yield

Imexpharm Corporation Announces Dividend, Payable on October 20, 2023

Upcoming dividend of ₫1,000 per share at 1.5% yield

Price target increased by 14% to ₫84,000

Second quarter 2023 earnings released

Imexpharm Corporation Appoints Chun Chaerhan as Chairperson of the Board of Directors

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings released: EPS: ₫3,495 (vs ₫2,600 in FY 2021)

Price target decreased to ₫66,600

Investor sentiment improved over the past week

No independent directors

Third quarter 2022 earnings released: EPS: ₫858 (vs ₫413 in 3Q 2021)

Imexpharm Corporation announced that it has received funding from SK Group Ltd.

Second quarter 2022 earnings released: EPS: ₫615 (vs ₫684 in 2Q 2021)

Price target increased to ₫79,000

Imexpharm Corporation Announces Personnel Change

Upcoming dividend of ₫1,500 per share

Imexpharm Corporation Announces Cash Dividend for 2021, Payable on June 24, 2022

No independent directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: EPS ₫413 (vs ₫478 in 3Q 2020)

Price target increased to ₫75,300

Second quarter 2021 earnings released: EPS ₫651 (vs ₫1,180 in 2Q 2020)

Upcoming dividend of ₫1,500 per share

First quarter 2021 earnings released: EPS ₫615 (vs ₫564 in 1Q 2020)

Full year 2020 earnings released: EPS ₫2,773 (vs ₫2,225 in FY 2019)

New 90-day high: ₫60,600

Revenue and earnings miss expectations

Full year 2020 earnings released: EPS ₫2,773

New 90-day high: ₫58,000

Price target raised to ₫57,910

New 90-day high: ₫56,800

New 90-day high: ₫54,900

New 90-day high: ₫49,550

Third quarter earnings released

New 90-day high - ₫49,500

New 90-day low - ₫39,650

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter